GlassScriptPhysician profile
Samantha Barker
NPI 1336805837
$1,036.67
in general payments reported to CMS, 2019-2025
23 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.79 · 2022: $49.98 · 2023: $281 · 2024: $250 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $245.87 | 2023-2024 | Myrisk |
| Incyte Corporation | $101.63 | 2022-2025 | Zynyz, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $80.49 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Tempus Ai, INC | $67.99 | 2024 | |
| Eisai INC. | $60.47 | 2022-2025 | |
| Seagen INC. | $55.36 | 2021-2023 | Adcetris, Padcev |
| Stemline Therapeutics INC. | $42.30 | 2024-2025 | Orserdu |
| W. L. Gore & Associates, INC. | $39.45 | 2021-2023 | Gore Enform Preperitoneal Biomaterial |
| Abbvie INC. | $32.27 | 2025 | |
| Janssen Biotech, INC. | $28.40 | 2023 | Imbruvica |
| Genmab U.S., INC. | $26.53 | 2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $26.02 | 2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $25.26 | 2025 | |
| Geron Corporation | $24.01 | 2025 | Rytelo |
| Progenics Pharmaceuticals, INC. | $23.21 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.89 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.11 | 2024 | Iclusig |
| Sobi, INC | $20.68 | 2025 | |
| Beigene USA, INC. | $20.42 | 2024 | Tevimbra |
| Ipsen Biopharmaceuticals, INC | $19.87 | 2025 | Onivyde |
| Lilly USA, LLC | $19.21 | 2024 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $18.10 | 2025 | Trodelvy |
| Genzyme Corporation | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.